Needham & Company Upgrades Imperva (IMPV) to Buy Amid Potential Sale; $64 PT
- Health, tech stocks extend Wall Street record-setting rally
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
- Exclusive: Japan's TDK in talks to buy iPhone supplier InvenSense - sources
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Needham & Company upgraded Imperva (NYSE: IMPV) from Hold to Buy with a price target of $64.00, as Qatalyst hired for a potential sale.
Analyst Scott Zeller commented, "Our IMPV downgrade post MarQ was based on our lack of confidence that IMPV could achieve its forecast for the year. IMPV missed in JuneQ and shares have since recovered from a low near $35, up to the current $45 range. Last night’s call with full details of the JuneQ miss lowered the bar materially, with CY16 guidance going down -18% from $305.5m to $249.6m at the midpoint. We believe the bar has now been lowered sufficiently for IMPV for CY16. The official news on the call of Qatalyst being hired confirms recent speculation, and we believe activist Elliott will likely be rewarded with a sale of IMPV. Valuation? Currently, shares are at 4x EV/CY17 on a very low bar of $318m in CY17. We estimate IMPV would be worth 6x EV/CY17 revenues or greater in a potential sale. Upgrade to BUY, new target $64, based on 6x EV/CY17 revenue."
Shares of Imperva closed at $45.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Finisar (FNSR) PT Raised to $44 at Needham & Company, Estimates Raised Sharply
- Xactly Corporation (XTLY): Lost Deals Create Buying Opportunity - Needham
- Jefferies Raises Price Target on Finisar (FNSR) to $37 Following 2Q Beat and Raise
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Upgrades, Rumors, Upgrades
Related EntitiesNeedham & Company
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!